

Under the Paperwork Reduction Act of 1995, no Persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if known	
				Application Number	10/550,313 Conf. No.: 8349
				Int' Appln. Filing Date	June 30, 2006
				First Named Inventor	John Eldridge
				Art Unit	1633
				Examiner Name	Kelaginamane T. Hiriyanna
Sheet	1	of	3	Attorney Docket Number	AM101319 (PCFC-439-101)

U.S. PATENT DOCUMENTS					
Examiner initials*	Cite No. ¹	Document Number Number - Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Documents	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		4,710,463	12-01-1987	Murray	
		5,589,466	12-31-1996	Felgner et al.	
		5,593,972	01-14-1997	Weiner et al.	

FOREIGN PATENT DOCUMENTS						
Examiner initials*	Cite No. ¹	Foreign Patent Document Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Documents	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶

NON PATENT LITERATURE DOCUMENTS			
Examiner initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
		ALLEN et al., "Tat-vaccinated macaques do not control simian immunodeficiency virus SIVmac239 replication," Journal of Virology, 76(8):4108-4112 (2002)	
		BROCKMAN et al., "Herpes simplex virus vectors elicit durable immune responses in the presence of preexisting host immunity," Journal of Virology, 76(8):3678-3687 (2002)	
		CLEMENTS-MANN et al., "Immune responses to human immunodeficiency virus (HIV) type 1 induced by canarypox expressing HIV-1 _{MN} gp120, HIV-1 _{SF2} recombinant gp120, or both vaccines in seronegative adults," The Journal of Infectious Disease, 177(5):1230-1246 (1998)	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Complete if known	
		Application Number	10/550,313 Conf. No.: 8349
		Int' Appln. Filing Date	June 30, 2006
		First Named Inventor	John Eldridge
		Art Unit	1633
		Examiner Name	Kelaginamane T. Hiriyanna
(use as many sheets as necessary)		Attorney Docket Number	AM101319 (PCFC-439-101)
Sheet	2	of	3

NON PATENT LITERATURE DOCUMENTS			
Examiner initials¹	Cite No.¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T²
		DAEMEN et al., "Immunization strategy against cervical cancer involving an alphavirus vector expressing high levels of a stable fusion protein of human papillomavirus 16 E6 and E7," Gene Therapy, 9(2):85-94 (2002)	
		EVANS et al., "Mucosal priming of simian immunodeficiency virus-specific cytotoxic T-lymphocyte responses in rhesus macaques by the <i>Salmonella</i> type III secretion antigen delivery system," Journal of Virology, 77(4):2400-2409 (2003)	
		GILBERT et al., "Heterologous expression of an immunogenic pneumococcal type 3 capsular polysaccharide in <i>Lactococcus lactis</i> ," Infection and Immunity, 68(6):3251-3260 (2000)	
		HANKE et al., "Construction and immunogenicity in a prime-boost regimen of a Semliki Forest virus-vectored experimental HIV clade A vaccine," Journal of General Virology, 84(Pt 2):361-368 (2003)	
		HARRINGTON et al., "Systemic, mucosal, and heterotypic immune induction in mice inoculated with Venezuelan equine encephalitis replicons expressing Norwalk virus-like particles," Journal of Virology, 76(2):730-742 (2002)	
		HÉCHARD et al., "Proteic boost enhances humoral response induced by DNA vaccination with the <i>dnaK</i> gene of <i>Chlamydia abortus</i> but fails to protect pregnant mice against a virulence challenge," Vet Res., 34(1):119-125 (2003)	
		HERMONAT et al., "Use of adeno-associated virus as a mammalian DNA cloning vector: transduction of neomycin resistance into mammalian tissue culture cells," Proc. Natl. Acad. Sci., 81(20):6466-6470 (1984)	
		HORTON et al., "Immunization of rhesus macaques with a DNA prime/modified vaccinia virus Ankara boost regimen induces broad simian immunodeficiency virus (SIV)-specific T-cell responses and reduces initial viral replication but does not prevent disease progression following challenge with pathogenic SIVmac239," Journal of Virology, 76(14):7187-7202 (2002)	

Examiner Signature		Date Considered	
-------------------------------	--	----------------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Complete if known	
		Application Number	10/550,313 Conf. No.: 8349
		Int' Appln. Filing Date	June 30, 2006
		First Named Inventor	John Eldridge
		Art Unit	1633
		Examiner Name	Kelaginamane T. Hiriyan
(use as many sheets as necessary)		Attorney Docket Number	AM101319 (PCFC-439-101)
Sheet	3	of	3

NON PATENT LITERATURE DOCUMENTS			
Examiner initials¹	Cite No.¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T²
		LEE et al., "Novel design architecture for genetic stability of recombinant poliovirus: the manipulation of G/C contents and their distribution patterns increases the genetic stability of inserts in a poliovirus-based RPS-Vax vector system," Journal of Virology, 76(4):1649-1662 (2002)	
		LOEHR et al., "Priming by DNA immunization augments T-cell responses induced by modified live bovine herpesvirus vaccine," Journal of General Virology, 82(Pt 12):3035-3043 (2001)	
		McDERMOTT et al., "Cytotoxic T-lymphocyte escape does not always explain the transient control of simian immunodeficiency virus SIVmac239 viremia in adenovirus-boosted and DNA-primed Mamu-A*01-positive rhesus macaques," Journal of Virology, 79(24):15556-15566 (2005)	
		PANG et al., "Development of dengue virus replicons expressing HIV-1 gp120 and other heterologous genes: a potential future tool for dual vaccination against dengue virus and HIV," BMC Microbiology, 1:28, 1-9 (2001)	
		QIAN et al., "Construction of a <i>tetR</i> -integrated <i>Salmonella enterica</i> serovar Typhi CVD908 strain that tightly controls expression of the major merozoite surface protein of <i>Plasmodium falciparum</i> for applications in human Vaccine production," Infection and Immunity, 70(4):2029-2038 (2002)	
		VINNER et al., "Immunogenicity in Mamu-A*01 rhesus macaques of a CCR5-tropic human immunodeficiency virus type 1 envelope from the primary isolate (Bx08) after synthetic DNA prime and recombinant adenovirus 5 boost," Journal of General Virology, 84(Pt 1):203-213 (2003)	
		WOODBERRY et al., "Prime boost vaccination strategies: CD8 T cell numbers, protection, and Th1 bias," The Journal of Immunology, 170(5):2599-2604 (2003)	
		XIANG et al., "Novel, chimpanzee serotype 68-based adenoviral vaccine carrier for induction of antibodies to a transgene product," Journal of Virology, 76(6):2667-2675 (2002)	

Examiner Signature		Date Considered	
-------------------------------	--	----------------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.